Reubi JC (2000). „In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.”. Ann N Y Acad Sci. 921 (1): 1—25. PMID11193811. doi:10.1111/j.1749-6632.2000.tb06946.x.
Basille M, Cartier D, Vaudry D, Lihrmann I, Fournier A, Freger P, Gallo-Payet N, Vaudry H, Gonzalez B (2006). „Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development”. J. Comp. Neurol. 496 (4): 468—78. PMID16572459. doi:10.1002/cne.20934.
Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008). „Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts”. Arthritis Rheum. 58 (4): 1086—95. PMID18383383. doi:10.1002/art.23403.
Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC, Kelly JS, Maywood ES, Hastings MH (2002). „The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei.”. Cell. 109 (4): 497—508. PMID12086606. doi:10.1016/S0092-8674(02)00736-5.
Cutler DJ, Haraura M, Reed HE, Shen S, Sheward WJ, Morrison CF, Marston HM, Harmar AJ, Piggins HD (2003). „The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro”. Eur. J. Neurosci. 17 (2): 197—204. PMID12542655. doi:10.1046/j.1460-9568.2003.02425.x.
Hughes AT, Fahey B, Cutler DJ, Coogan AN, Piggins HD (2004). „Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor”. J. Neurosci. 24 (14): 3522—6. PMID15071099. doi:10.1523/JNEUROSCI.5345-03.2004.
Asnicar MA, Köster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF, Hsiung HM (2002). „Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate”. Endocrinology. 143 (10): 3994—4006. PMID12239111. doi:10.1210/en.2002-220354.
Reubi JC (2000). „In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.”. Ann N Y Acad Sci. 921 (1): 1—25. PMID11193811. doi:10.1111/j.1749-6632.2000.tb06946.x.
Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000). „Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.”. Cancer Res. 60 (11): 3105—3112. PMID10850463.
Basille M, Cartier D, Vaudry D, Lihrmann I, Fournier A, Freger P, Gallo-Payet N, Vaudry H, Gonzalez B (2006). „Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development”. J. Comp. Neurol. 496 (4): 468—78. PMID16572459. doi:10.1002/cne.20934.
Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008). „Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts”. Arthritis Rheum. 58 (4): 1086—95. PMID18383383. doi:10.1002/art.23403.
Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC, Kelly JS, Maywood ES, Hastings MH (2002). „The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei.”. Cell. 109 (4): 497—508. PMID12086606. doi:10.1016/S0092-8674(02)00736-5.
Cutler DJ, Haraura M, Reed HE, Shen S, Sheward WJ, Morrison CF, Marston HM, Harmar AJ, Piggins HD (2003). „The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro”. Eur. J. Neurosci. 17 (2): 197—204. PMID12542655. doi:10.1046/j.1460-9568.2003.02425.x.
Hughes AT, Fahey B, Cutler DJ, Coogan AN, Piggins HD (2004). „Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor”. J. Neurosci. 24 (14): 3522—6. PMID15071099. doi:10.1523/JNEUROSCI.5345-03.2004.
Asnicar MA, Köster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF, Hsiung HM (2002). „Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate”. Endocrinology. 143 (10): 3994—4006. PMID12239111. doi:10.1210/en.2002-220354.
Zhang ZH, Wu SD, Gao H, Shi G, Jin JZ, Kong J, Tian Z, Su Y (2006). „Expression of pituitary adenylate cyclase-activating polypeptide 1 and 2 receptor mRNA in gallbladder tissue of patients with gallstone or gallbladder polyps”. World J. Gastroenterol. 12 (9): 1468—71. PMID16552823.